Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors was written by Ishida, Hiroshi;Isami, Shoichi;Matsumura, Tsutomu;Umehara, Hiroshi;Yamashita, Yoshinori;Kajita, Jiro;Fuse, Eiichi;Kiyoi, Hitoshi;Naoe, Tomoki;Akinaga, Shiro;Shiotsu, Yukimasa;Arai, Hitoshi. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2008.SDS of cas: 625438-03-1 The following contents are mentioned in the article:
5-(1,3,4-Oxadiazol-2-yl)pyrimidine derivative 1 was identified as a new class of FLT3 inhibitor from our compound library. With the aim of enhancement of antitumor activity of 2 prepared by minor modification of 1, structure optimization of side chains at the 2-, 4-, and 5-positions of the pyrimidine ring of 2 was performed to improve the metabolic stability. Introduction of polar substituents on the 1,3,4-oxadiazolyl group contributed to a significant increase in the metabolic stability. As a result, a series of compounds showed increased efficacy against MOLM-13 xenograft model in mice by oral administration. This study involved multiple reactions and reactants, such as 2-(2-Methylpyridin-4-yl)ethanamine (cas: 625438-03-1SDS of cas: 625438-03-1).
2-(2-Methylpyridin-4-yl)ethanamine (cas: 625438-03-1) belongs to pyridine derivatives. Pyridine is diamagnetic and has a diamagnetic susceptibility of 鈭?8.7 脳 10鈭? cm3路mol鈭?.The molecular electric dipole moment is 2.2 debyes. The standard enthalpy of formation is 100.2 kJ路mol鈭? in the liquid phase and 140.4 kJ路mol鈭? in the gas phase. Pyridine derivatives are also useful as small-molecule 伪-helix mimetics that inhibit protein-protein interactions, as well as functionally selective GABA ligands.SDS of cas: 625438-03-1